Company Overview of Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc., a research-based pharmaceutical company, focuses on the discovery, development, and commercialization of molecules and therapies to help improve the lives of people who suffer from rare diseases. The company offers prescription pharmaceuticals for rare diseases that include tablets, oral solutions, sugar-free oral solutions, and injections; and capsules. It also offers nonprescription medicines and dietary supplements that help to support the normal functions of body. In addition, the company provides third party manufacturing services for customers in the United States, Canada, Mexico, Brazil, Europe, the Middle East, and Africa. Its products cover areas, su...
9841 Washingtonian Boulevard
Gaithersburg, MD 20878
Founded in 1980
Key Executives for Sigma-Tau Pharmaceuticals, Inc.
Senior Director of Finance
Chief Executive Officer of Sigma-Tau Group
Vice President of Medical Affairs
Vice President of Clinical Affairs
Compensation as of Fiscal Year 2014.
Sigma-Tau Pharmaceuticals, Inc. Key Developments
Sigma-Tau Pharmaceuticals Names Dave Lemus as Chief Executive
Aug 18 14
Sigma-Tau Pharmaceuticals appointed Dave Lemus as chief executive.
Sigma-Tau Pharmaceuticals, Inc. Signs License Agreement with Crosscare Limited
Aug 13 14
Sigma-Tau Pharmaceuticals, Inc. announced that it has signed an exclusive United States license agreement with Crosscare Limited to market and distribute Colief Infant Drops for the treatment of colic. Under the multi-year license agreement, Sigma-Tau will be responsible for the sales, marketing and distribution of Colief in the United States.
Sigma-Tau Pharmaceuticals, Inc. Announces Availability of CYSTARAN(TM) 0.44%
May 1 13
Sigma-Tau Pharmaceuticals, Inc. announced the availability of CYSTARAN(TM) (cysteamine ophthalmic solution) 0.44%, the first and only FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis. Sigma-Tau developed CYSTARAN in partnership with the National Institutes of Health (NIH) and in cooperation with the Cystinosis Foundation, the Cystinosis Research Foundation, and the Cystinosis Research Network. The U.S. Food and Drug Administration (FDA) approved CYSTARAN in October 2012, and the product has also been granted Orphan Drug status. CYSTARAN is available as a sterile ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|